The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.

Rheumatology
I OlivieriPACE working group

Abstract

To evaluate costs, benefits and cost-effectiveness of anti-TNF agents in PsA patients with inadequate response to conventional treatment. A total of 107 patients, from nine Italian rheumatology centres, with different forms of PsA were given anti-TNF treatment, mainly etanercept (87%). Information on resource use, health-related quality of life, disease activity, function and laboratory values were collected at baseline and through out the 12 months of therapy. Cost (expressed in euro 2007) and utility (measured by EuroQol) before and after anti-TNF therapy initiation were compared in order to estimate the incremental cost per quality-adjusted life year (QALY) gained, and cost-effectiveness acceptability curve was calculated. At the end of 12 months, there was a significant increase in direct cost due to an increase of drug cost caused by TNF inhibitors that was only partially offset by the decrease in indirect cost. In the last 6 months of therapy, the direct cost increased by euro5052, the cost for the National Health System (NHS) by euro5044 and the social cost by euro4638. However, a gain of 0.12 QALY resulted in a cost per QALY gained of euro40 876 for the NHS and of euro37 591 for the society. The acceptability curve show...Continue Reading

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Aug 1, 1991·British Journal of Rheumatology·J C Torre AlonsoC Lopez Larrea
Nov 1, 1969·Annals of the Rheumatic Diseases·I F Macrae, V Wright
Jan 1, 1980·Arthritis and Rheumatism·P Hasselbacher
Feb 1, 1980·Arthritis and Rheumatism·J F FriesH R Holman
Nov 21, 1997·Medical Care·P Dolan
Nov 17, 1998·Journal of Clinical Epidemiology·G Apolone, P Mosconi
Jun 6, 1996·Health Policy·R Brooks
Feb 24, 2001·Medical Decision Making : an International Journal of the Society for Medical Decision Making·X BadiaP Kind
Jun 14, 2002·Journal of the American Academy of Dermatology·Harold S JavitzSusan Gillis Vallow
Jan 15, 2003·Annals of the Rheumatic Diseases·L Heuft-DorenboschD van der Heijde
Jan 20, 2004·Arthritis and Rheumatism·Dafna D GladmanWilliam Taylor
Jul 13, 2004·Arthritis and Rheumatism·Philip J MeaseWayne Tsuji
Feb 15, 2005·Annals of the Rheumatic Diseases·D D GladmanP Nash
Oct 4, 2005·Arthritis and Rheumatism·Philip J MeaseUNKNOWN Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group
Mar 17, 2006·Annals of the Rheumatic Diseases·D HuscherUNKNOWN German Collaborative Arthritis Centres
Jun 8, 2006·Health and Quality of Life Outcomes·Monali J BhosleRajesh Balkrishnan

❮ Previous
Next ❯

Citations

Apr 22, 2009·Rheumatology International·Valentin BrodszkyLászló Gulácsi
Mar 24, 2010·Zeitschrift für Rheumatologie·J Hermann
May 4, 2012·Clinical Rheumatology·Ennio Lubrano, Antonio Spadaro
Dec 31, 2009·Rheumatology·Rieke J B DriessenFrank H J van den Hoogen
Jan 5, 2011·International Journal of Rheumatic Diseases·Fabrizio CantiniEmanuele Cassarà
Mar 15, 2014·Actas dermo-sifiliográficas·J D Cañete, L Puig
Mar 29, 2014·Actas dermo-sifiliográficas·A López-Ferrer, A Laiz-Alonso
Aug 21, 2009·Current Rheumatology Reports·Ignazio OlivieriSimona de Portu
Aug 21, 2009·Current Rheumatology Reports·Enrique R Soriano, Javier Rosa
Oct 2, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Paweł Kawalec, Krzysztof Piotr Malinowski
May 14, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Reginald VillacortaAndrew Messali
Nov 18, 2015·Expert Opinion on Biological Therapy·Tristan Boyd, A Kavanaugh
Jul 9, 2011·Expert Opinion on Pharmacotherapy·Jonathan P StaidleSteven R Feldman
Dec 8, 2011·Arthritis Care & Research·Penélope Esther PalominosLaure Gossec
Mar 6, 2010·Journal of the European Academy of Dermatology and Venereology : JEADV·R ScarpaA Giannetti
Oct 30, 2016·International Journal of Rheumatic Diseases·Tsong-Shing YangKo-Ming Lin
Jul 23, 2014·Arthritis Care & Research·Philip HelliwellRuben Queiro
Apr 17, 2015·Neuromodulation : Journal of the International Neuromodulation Society·Furio ZuccoLorenzo G Mantovani
Aug 21, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Luciana ScaloneLorenzo G Mantovani
Jan 8, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Ewen CumminsElisabeth Fenwick
Aug 8, 2015·Arthritis & Rheumatology·Raffaele Scarpa
Jun 19, 2016·Actas dermo-sifiliográficas·R Burgos-PolM Á Casado
Jun 25, 2016·Rheumatology International·Paweł KawalecAndrzej Pilc
Aug 28, 2016·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Luciana Scalone, Paolo A Cortesi
Jun 28, 2017·PloS One·Paolo Angelo CortesiLorenzo Giovanni Mantovani
Oct 16, 2015·BMJ Open Gastroenterology·Luciana ScaloneLorenzo Giovanni Mantovani
Nov 3, 2012·The Journal of Rheumatology·Alberto CauliIgnazio Olivieri
Jun 3, 2010·The Journal of Rheumatology·Ignazio OlivieriAngela Padula
Feb 25, 2009·Expert Opinion on Pharmacotherapy·Ignazio OlivieriAngela Padula
Feb 25, 2015·The Nurse Practitioner·Kori A Dewing
Feb 12, 2019·Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·Massimo RalliDavid Bächinger
May 6, 2017·Clinical Rheumatology·Sergio SchwartzmanJacqueline B Palmer

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR

Software Mentioned

SPSS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.